South Korea · Delayed Price · Currency is KRW Bio Solution Statistics
Total Valuation
Bio Solution has a market cap or net worth of KRW 169.28 billion. The enterprise value is 176.80 billion.
| Market Cap | 169.28B |
| Enterprise Value | 176.80B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bio Solution has 25.80 million shares outstanding. The number of shares has increased by 2.83% in one year.
| Current Share Class | 25.80M |
| Shares Outstanding | 25.80M |
| Shares Change (YoY) | +2.83% |
| Shares Change (QoQ) | +3.35% |
| Owned by Insiders (%) | 17.71% |
| Owned by Institutions (%) | 0.01% |
| Float | 21.23M |
Valuation Ratios
The trailing PE ratio is 186.70.
| PE Ratio | 186.70 |
| Forward PE | n/a |
| PS Ratio | 9.73 |
| PB Ratio | 4.10 |
| P/TBV Ratio | 4.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 203.47 |
| EV / Sales | 10.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of 0.46.
| Current Ratio | 0.84 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | -95.65 |
| Interest Coverage | -1.30 |
Financial Efficiency
Return on equity (ROE) is 2.50% and return on invested capital (ROIC) is -3.58%.
| Return on Equity (ROE) | 2.50% |
| Return on Assets (ROA) | -3.25% |
| Return on Invested Capital (ROIC) | -3.58% |
| Return on Capital Employed (ROCE) | -7.67% |
| Weighted Average Cost of Capital (WACC) | 4.33% |
| Revenue Per Employee | 85.69M |
| Profits Per Employee | 4.28M |
| Employee Count | 203 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 3.34 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.91% in the last 52 weeks. The beta is -0.12, so Bio Solution's price volatility has been lower than the market average.
| Beta (5Y) | -0.12 |
| 52-Week Price Change | -32.91% |
| 50-Day Moving Average | 6,206.80 |
| 200-Day Moving Average | 8,365.80 |
| Relative Strength Index (RSI) | 51.95 |
| Average Volume (20 Days) | 105,653 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio Solution had revenue of KRW 17.39 billion and earned 868.96 million in profits. Earnings per share was 35.14.
| Revenue | 17.39B |
| Gross Profit | 11.40B |
| Operating Income | -3.37B |
| Pretax Income | 868.96M |
| Net Income | 868.96M |
| EBITDA | -1.04B |
| EBIT | -3.37B |
| Earnings Per Share (EPS) | 35.14 |
Balance Sheet
The company has 11.62 billion in cash and 19.15 billion in debt, with a net cash position of -7.53 billion or -291.72 per share.
| Cash & Cash Equivalents | 11.62B |
| Total Debt | 19.15B |
| Net Cash | -7.53B |
| Net Cash Per Share | -291.72 |
| Equity (Book Value) | 41.31B |
| Book Value Per Share | 1,627.63 |
| Working Capital | -3.65B |
Cash Flow
In the last 12 months, operating cash flow was -46.36 million and capital expenditures -153.86 million, giving a free cash flow of -200.22 million.
| Operating Cash Flow | -46.36M |
| Capital Expenditures | -153.86M |
| Depreciation & Amortization | 2.33B |
| Net Borrowing | -950.64M |
| Free Cash Flow | -200.22M |
| FCF Per Share | -7.76 |
Margins
Gross margin is 65.52%, with operating and profit margins of -19.35% and 5.00%.
| Gross Margin | 65.52% |
| Operating Margin | -19.35% |
| Pretax Margin | 5.00% |
| Profit Margin | 5.00% |
| EBITDA Margin | -5.98% |
| EBIT Margin | -19.35% |
| FCF Margin | n/a |
Dividends & Yields
Bio Solution does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.83% |
| Shareholder Yield | -2.83% |
| Earnings Yield | 0.51% |
| FCF Yield | -0.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 27, 2025. It was a forward split with a ratio of 3.
| Last Split Date | May 27, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Bio Solution has an Altman Z-Score of 4.4 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.4 |
| Piotroski F-Score | 3 |